Abbott Laboratories (ABT)
| Market Cap | 206.31B |
| Revenue (ttm) | 41.22B |
| Net Income (ttm) | 5.74B |
| Shares Out | 1.73B |
| EPS (ttm) | 3.29 |
| PE Ratio | 36.15 |
| Forward PE | 23.53 |
| Dividend | $2.20 (1.85%) |
| Ex-Dividend Date | Oct 15, 2024 |
| Volume | 3,252,494 |
| Open | 118.35 |
| Previous Close | 117.96 |
| Day's Range | 118.10 - 120.53 |
| 52-Week Range | 99.71 - 121.64 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 129.25 (+8.66%) |
| Earnings Date | Jan 22, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, Abbott Laboratories's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.70 billion, a decrease of -17.44%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $129.25, which is an increase of 8.66% from the latest price.
News
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis
The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The inves...
Abbott Laboratories: Investors Should Wait For A Pullback
Abbott has a very stable gross profit margin, while the company's revenue and return on invested capital could be more consistent. The company has increased their dividend for more than 50 years and s...
MACH Alliance Expands Education Program, Appoints Dylan Valade of Abbott As Head of Education
NEW YORK--(BUSINESS WIRE)--MACH Alliance, a not-for-profit industry body dedicated to advocating for open, best-of-breed technology ecosystems, today announced the expansion of its thriving education ...
Abbott India posts Q2 profit rise on strong demand, price hikes
Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
The lawsuits against Abbott 'really steam me', says Jim Cramer
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Jim Cramer takes a closer looks at the litigation facing Abbott and what it means for the company
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win
Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's de...
Abbott shares rise after securing first win in premature infant formula trial
Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.
Abbott Labs and Reckitt Benckiser shares surge on court's baby formula ruling
A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC
Abbott, Reckitt cleared of liability in latest preterm formula case
Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit accusing them of failing to warn of their premature ba...
Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead
A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for ...
My Best Dividend Aristocrats For November 2024
The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the ...
Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott collaborate to integrate data, expand patient choice, and improve clinical workflows.
CORRECTING and REPLACING Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott partner to integrate data, expand patient choice, and improve clinical workflows.
Seamless Data: Tidepool and Abbott's New Cloud-to-Cloud Integration Partnership
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott partner to integrate data, expand patient choice, and improve clinical workflows.
FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach
CHICAGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union (ALEC) data breach, which, according ...
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developi...
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock
Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue ...
What Drove Abbott's Q3?
Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share and...
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices, contributing to steady growth and consistent dividends. ABT's Q2 earnings showed solid perfo...
3 Fortune 500 Industry Leaders Boast Ideal October Dividends
The June/July 2024 edition of Fortune revealed the 500 biggest U.S. companies by revenue and profits. Dogcatcher's quest to sniff-out the best dividend-buys focused on 66 industry-leader profits per Y...
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.